Next-generation sequencing, should I use anti-HER2 therapy for HER2-amplified tumors off-label? Illustrating an extrapolation framework

Doah Cho, Sarah J. Lord, John Simes, Wendy Cooper, Michael Friedlander, Susie Bae and Chee Khoon Lee

Abstract

Background: Next-generation sequencing is used to increase targeted treatment opportunities, particularly for patients who have exhausted standard options. Where randomized controlled trial evidence for a targeted therapy is available for molecular alterations in one tumor type, the dilemma for the clinician is whether ‘matching’ targeted agents should be recommended off-label for the same molecular alterations detected in other tumor types, for which no trial data are available to guide practice. To judge the likely benefits, it may be possible to extrapolate evidence from cancers where treatment benefits have been established.

Methods: We present a framework for assessing the appropriateness of extrapolation using trastuzumab, an anti-HER2 antibody, for HER2-amplified tumors where trastuzumab use would be off-label as an illustrative example.

Results: The following should be considered for the tumor type where trastuzumab would be off-label: (a) reliability of the NGS assay for detecting HER2 amplification; (b) criteria for defining HER2 positivity; (c) strength of evidence supporting the actionability of HER2 amplification and trastuzumab; (d) whether better clinical outcomes with trastuzumab are due to a more favorable natural history rather than trastuzumab effect; (e) signals of trastuzumab activity and whether it translates to clinically meaningful benefit; (f) whether the safety profile of trastuzumab differs from established indications; and (g) discussion points for shared decision making (SDM) to facilitate informed consent.

Conclusion: We present a systematic approach for appraising evidence to support extrapolating trastuzumab benefits from established indications to off-label applications. Extrapolation criteria and areas of uncertainty to inform SDM are outlined. This framework is potentially generalizable to other tumor-agnostic biomarker-targeted therapy scenarios. It is a practical approach for clinicians to apply in routine practice and should be considered by molecular tumor boards who make off-label recommendations.

Keywords: gene expression profiling, HER2-targeted therapy, molecular testing, predictive biomarker, targeted therapy, tumor biology

Introduction

Next-generation sequencing (NGS) is increasingly used for comprehensive molecular profiling to increase targeted treatment opportunities, particularly for advanced cancer patients who have exhausted standard options. Where randomized controlled trial (RCT) evidence for a targeted therapy is available for molecular alterations...
in one tumor type, the clinician’s dilemma is whether ‘matching’ targeted agents should be recommended off-label for the same alterations detected in other tumor types, if RCT data are unavailable to guide practice. This is already a common recommendation from molecular tumor boards (MTBs) if appropriate clinical trials are unavailable,1 with few presenting the strength of recommendations using standard level of evidence scales.2,3

To illustrate, human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase receptor encoded by the ERBB2 (HER2) gene (chromosome 17q12). Overexpression of HER2 protein occurs mainly from HER2 gene amplification4 and results in oncogenic signaling.5 Clinical benefit of targeting HER2 amplification by adding anti-HER2 therapy to chemotherapy has been established in RCTs in breast,6–8 gastric and gastroesophageal (GE),9 and uterine serous cancers.10 Since HER2 amplification is also detected in other cancer types, there is high interest in whether this clinical benefit also applies.11

To estimate the benefits of adding trastuzumab, an anti-HER2 antibody, to chemotherapy in HER2-amplified cancers where there is no RCT data, hereby referred to as ‘off-label trastuzumab’, it may be possible to extend data from cancers where clinical benefit of this treatment has been established in RCTs (‘established indications’). However, extrapolation may not be appropriate in some settings because of biological differences between cancers. We present a framework for extrapolation and illustrate its application using off-label trastuzumab. The aim of this exercise is to help clinicians apply these principles which may be generalizable to other biomarker-targeted therapy scenarios.

**Methods**

We developed a framework to assess the appropriateness of extrapolating data from established indications to other cancers. This framework is articulated through a series of questions and addresses the distinct components required for extrapolation: analytical validity of the biomarker test, biomarker criteria to define the disease, strength of evidence supporting biomarker actionability, natural history of biomarker-defined cancers, signals of targeted therapy response, and similarity of safety profile. A prescriptive step-wise approach is not proposed as the evidence supporting each question for different biomarker-targeted therapy scenarios will likely be different. Alternative therapies available and costs will also be different for each scenario. Cost should be addressed upfront as further considerations will be futile if there is no reasonable way to cover the cost of off-label therapy.

Using the example of HER2-amplified cancers and the accompanying treatment trastuzumab, this article demonstrates the application of the framework. We limit the discussion to trastuzumab for illustration clarity although many other HER2-directed therapies exist. This work is not intended to provide a comprehensive review of the biology and management of HER2-amplified tumors.

**Results**

We outline seven questions to consider when estimating the benefit of off-label trastuzumab (Figure 1). The order of the questions is built around the Population, Intervention, Comparator, and Outcome (PICO) model to define the information needed to address our clinical question.12,13 Questions 1 and 2 address defining the disease population according to HER2 amplification status. Question 3 addresses the ability of HER2 amplification status to predict trastuzumab effect. Question 4 addresses the treatment outcomes of the HER2 amplified population on standard of care control treatment. Question 5 addresses signals of trastuzumab efficacy based on surrogate endpoints, and question 6 addresses the safety profile of off-label trastuzumab. Questions 1 to 6 should be considered individually, and judgment for the level of uncertainty for extrapolation should be made for each (Table 1).14 Responses from other extrapolation questions either increase or decrease certainty of each question and the final treatment recommendation should be made based on the totality of the evidence. If there is probably no important uncertainty for most of the questions, then there is likely sufficient evidence to support off-label trastuzumab. However, if there is important uncertainty for many or most of the questions, there is insufficient evidence to support off-label trastuzumab. Question 7 addresses shared decision-making (SDM) and informed consent for recommendations made after considering questions 1–6. Recommendations should be individualized and consider the estimated benefit versus
Analytical validity of the biomarker test
How reliable is the NGS assay for detecting HER2 amplification across diverse cancers compared to conventional testing methods? In breast and gastric/GE junction cancers, the American Society of Clinical Oncology and the College of American Pathologists recommend testing for HER2 protein overexpression using immunohistochemistry (IHC) and HER2 gene amplification using fluorescent or silver in situ hybridization (FISH or

**Table 1.** Assessment of uncertainty when extrapolating evidence for off-label application.

| Judgment*          | Evidence Assessed for each question* | Treatment recommendation Assessed from evidence for all questions# |
|--------------------|--------------------------------------|---------------------------------------------------------------|
| Important uncertainty | No research evidence identified or searched for | Insufficient evidence to support off-label therapy |
| Possibly important uncertainty | Judgment Responses from other extrapolation questions decrease certainty | Possibly sufficient evidence to support off-label therapy |
| Probably no important uncertainty | Judgment Responses from other extrapolation questions increase certainty | Likely sufficient evidence to support off-label therapy |

Source: Adapted from ‘Standardized wording to improve efficiency and clarity of GRADE EID frameworks in health guidelines’. *J Clin Epidemiol* 2022; 146: 106–122.

*Judgment for the level of uncertainty for extrapolation should be made individually for each of the questions from 1 to 6. Responses from other extrapolation questions either increase or decrease certainty of each question.

#The final treatment recommendation should be made based on the totality of the evidence. If there is probably no important uncertainty for most of the questions, then there is likely sufficient evidence to support off-label therapy. However, if there is important uncertainty for many or most of the questions, there is insufficient evidence to support off-label therapy. Treatment recommendations should be individualized and consider estimated benefit versus risks of off-label therapy compared to alternative therapies if available.
Therapeutic advances in Medical Oncology

Volume 14

Table 2. Measures of concordance and accuracy.

| Biomarker test – NGS | Evidentiary standard – IHC and FISH |
|----------------------|----------------------------------|
| HER2-amplified       | A                               |
| HER2 non-amplified   | B                               |
|                      | C                               |
|                      | D                               |

Concordance is measured by cross-classifying the results of two tests. In this example, the overall concordance between the biomarker test (NGS) and the evidentiary standard (IHC and FISH) can be expressed as a percentage of A + D/ [A + B + C + D].

Accuracy measures include test sensitivity, specificity, PPV, and NPV. The analytical sensitivity and specificity of the NGS assay can be assessed using reference samples, either patient samples or cell lines, which show varying degrees of HER2 amplification. PPV and NPV refer to the proportion of patients who test positive and negative, respectively, by the NGS assay, who also have (or do not have) HER2 amplification when measured by evidentiary standard tests, a widely accepted orthogonal test, or subsequent established technologies. PPV = A/(A + B), NPV = D/(C + D). PPV and NPV depend on the prevalence of HER2 amplification in the tested population. For an NGS assay with a given analytical sensitivity and specificity, PPV will be poorer if HER2 amplification prevalence is lower and NPV will be poorer if HER2 amplification prevalence is higher. Poorer PPV and NPV will result in a greater chance of incorrectly classifying a patient as having HER2 amplification when they do not (false positive), or not having HER2 amplification when they do (false negative) and can result in incorrect trastuzumab recommendations, poorer clinical outcomes, and wasted resources.

FISH, fluorescent in situ hybridization; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; NGS, next-generation sequencing; NPV, negative predictive value; PPV, positive predictive value.

SISH) to select patients for trastuzumab. IHC and FISH/SISH are considered ‘evidentiary standard’ tests as they were used in pivotal RCTs to identify HER2-positive patients and demonstrated the survival benefit of adding trastuzumab to chemotherapy in these cancers (‘clinical validity’). However, when using a different test, such as an NGS assay, concordance with these evidentiary standards should be assessed to determine reliability of results (‘analytical validity’, Table 2). When discordance exists, and the evidentiary standard is considered the best available indicator of the true biological state, accuracy measures are useful for assessing the performance of the different test. However, when technology has advanced following the pivotal treatment trial, the new test may be considered a more valid measure of the biological target, and accuracy measures are not clinically interpretable. However, assessment of discordance is important for transparency because treatment evidence for cancers defined by the evidentiary standard alone is being transported to a different cancer type defined by a different test, introducing some uncertainty about the size of clinical benefit for the NGS-defined patients.

Concordance of an NGS assay with IHC and/or FISH (IHC/FISH) can differ across cancers due to differences in biology, tumor sampling, and/or tissue processing techniques. The Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets assay is an NGS assay that has been analytically validated in breast and GE cancers, and concordance was 97.1 and 78.8%, respectively, among cases amplified by IHC/FISH.

For NGS assays, tumor content of sampled tissue and intratumoral heterogeneity (genetic diversity of tumor clones within a single patient) can affect test accuracy and may in part explain lower concordance in GE cancers. In GE cancers, samples obtained via endoscopic biopsy tend to be smaller and intratumoral heterogeneity more prevalent than in breast cancers (79% versus 18% respectively). Unlike NGS, IHC/FISH assays enable simultaneous tumor morphological assessment so that heterogeneity can be considered and invasive carcinoma (which should be assessed for HER2 amplification) can be distinguished from in situ carcinoma and non-neoplastic tissue (which should not be included in HER2 status assessment).

Concordance of different NGS assays with IHC/FISH developed by different laboratories may also differ. Performance characteristics such as the minimum tumor content required for an accurate test result and limits of detection, which refers to the lowest variant allele frequency that can be reliably detected can differ between NGS assays.

Prevalence of HER2 amplification varies widely across different cancers, as outlined in Table 3. Differences in prevalence can also affect the usefulness of the same assay to identify the HER2-amplified population as illustrated in Table 4. For cancer types that have not yet been assessed in...
RCTs, studies assessing analytical validation of NGS may not even be performed.

**Biomarker criteria**

*Have the criteria used to define HER2 positivity been assessed in the cancer type for off-label trastuzumab?* The criteria used to define HER2 amplification on NGS may differ across different cancers. In uterine serous carcinoma (USC) and colorectal cancer (CRC), HER2 amplification, defined as HER2 gene copy number of six or more, was found to have perfect concordance with HER2 amplification defined by standard criteria (2018 ASCO/CAP breast cancer criteria for USC and HERACLES Diagnostic Criteria for CRC).²⁰,²¹ However, studies in breast cancer showed the same cut-off did not have adequate sensitivity,¹⁷ whereas a lower copy number cut-off of 3.2 or more was found to have 100% sensitivity and 98.5% specificity against standard criteria.²² There are frequently no cancer-specific criteria to define HER2 positivity available for cancers outside established indications and decisions to use off-label trastuzumab for these cancers, based on criteria for other cancers involve further uncertainty of clinical benefit.

HER2 amplification should also be differentiated from HER2 mutations. Somatic HER2 mutations have been identified in all exons of the gene encoding various domains of the HER2 protein.²³ These mutations have been found in multiple cancers, with varying prevalence,²³,²⁴ some

| Cancer type                        | Estimated number of new cases in 2020 | Crude Rate (per 100,000) | Frequency of HERBB2 amplification (%) |
|-----------------------------------|--------------------------------------|--------------------------|--------------------------------------|
| Esophagogastric adenocarcinoma    | 604,100                              | 7.8                      | 15.8                                 |
| Undifferentiated stomach adenocarcinoma | 1,089,103                        | 14.0                     | 15.8                                 |
| Cervical adenocarcinoma           | 604,127                              | 15.6                     | 13.0                                 |
| Breast invasive carcinoma         | 2,261,419                            | 58.5                     | 11.5                                 |
| Endometrial carcinoma             | 417,367                              | 10.8                     | 5.5                                  |
| Bladder urothelial carcinoma      | 573,278                              | 7.4                      | 5.4                                  |
| Pancreatic adenocarcinoma         | 495,773                              | 6.4                      | 4.9                                  |
| Cervical squamous cell carcinoma  |                                      |                          | 4.1                                  |
| Colorectal adenocarcinoma         | 1,931,590                            | 24.8                     | 3.4                                  |
| Esophageal squamous cell carcinoma|                                      |                          | 3.2                                  |
| Ovarian epithelial tumor          | 313,959                              | 8.1                      | 2.3                                  |
| Non-small cell lung cancer        | 2,206,771                            | 28.3                     | 2.1                                  |
| Head and neck squamous cell carcinoma | 1,116,546                        | 14.4                     | 2.1                                  |
| Hepatocellular carcinoma          | 905,677                              | 11.6                     | 0.8                                  |
| Prostate adenocarcinoma           | 1,414,259                            | 36.0                     | 0.4                                  |
| Melanoma                          | 324,635                              | 4.2                      | 0.3                                  |
| Well-differentiated thyroid carcinoma | 586,202                          | 7.5                      | 0.2                                  |
| Renal clear cell carcinoma        | 431,288                              | 5.5                      | 0.2                                  |

All cancer incidences were obtained from 2020 data from the International Agency for Research on Cancer https://gco.iarc.fr/ and is based on organ of origin. Data for ERBB2 amplification frequency were collected from cBioPortal from 10,953 patients/10,967 samples from 32 The Cancer Genome Atlas, Pan Cancer Atlas studies.
variants predicted as driver mutations while others passangers,\textsuperscript{25} and in most cases have not been associated with concurrent gene amplification.\textsuperscript{26–28} Unlike \(\text{HER2}\) amplification, which predicts trastuzumab sensitivity for established indications, \(\text{HER2}\) mutations are diverse, with some showing trastuzumab sensitivity, while others not, and some conferring trastuzumab resistance.\textsuperscript{24,25} A single mutation may also confer differential sensitivity to trastuzumab and other anti-\(\text{HER2}\) therapies.\textsuperscript{29} Compared to \(\text{HER2}\) amplification, clinical studies testing anti-\(\text{HER2}\) therapy for \(\text{HER2}\) mutations in various cancers are limited at present to a few small prospective studies and retrospective analyses and show wide-ranging results, raising uncertainty regarding targetability of \(\text{HER2}\) mutations for specific cancers.\textsuperscript{23,30–32}

**Table 4.** Predictive values for an assay with 99% sensitivity and 95% specificity for \(\text{ERBB2}\) amplification across two tumor types with different prevalence rates.

|                         | GE adenocarcinoma | Renal cell carcinoma |
|-------------------------|-------------------|---------------------|
| Prevalence of \(\text{ERBB2}\) amplification, % | 15.8 | 0.2 |
| Population, no.         | 1000             | 1000                |
| Amplification, no.      | 158              | 2                   |
| No amplification, no.   | 842              | 998                 |
| TP, no.                 | 156              | 2                   |
| FP, no.                 | 42               | 50                  |
| TP plus FP, no.         | 198              | 52                  |
| PPV, %                  | 79               | 4                   |

FP, false positive; GE, gastroesophageal; PPV, positive predictive value; TP, true positive.

natural history of biomarker-defined groups

Could better outcome of patients with \(\text{HER2}\)-amplified cancers treated with off-label trastuzumab be due to a more favorable natural history rather than the trastuzumab effect? Natural history, or prognosis, of a cancer population refers to the clinical outcomes experienced because of the biology of the cancer independent of treatment received. Although cancer-specific natural history is well-established, natural history of biomarker-defined subgroups may not yet be described. Pivotal trials showed median overall survival (OS) was longer in breast (20.3 months)\textsuperscript{6} than in gastric/GE cancer (11.1 months)\textsuperscript{9} in the control arms receiving cancer-specific chemotherapy and all patients with \(\text{HER2}\)-amplified tumors. \(\text{HER2}\) amplification can also affect natural history, but its prognostic effect

**Biomarker actionability**

How strong is the evidence supporting actionability of \(\text{HER2}\) amplification and off-label trastuzumab? A biomarker is ‘actionable’ if treatment selection based on biomarker status improves clinical outcomes compared to decisions made without it. Actionability describes ‘co-dependency’ between biomarker and targeted treatment and is considered broadly across and between different cancers expressing the biomarker. The actionability of \(\text{HER2}\) amplification has been demonstrated in multiple prospective RCTs that showed adding trastuzumab to chemotherapy in breast,\textsuperscript{6,7} advanced gastric/GE,\textsuperscript{9} and advanced uterine serous cancers\textsuperscript{10} resulted in a clinically meaningful survival improvement when compared with chemotherapy alone. However, in cancers where this evidence is not available, published frameworks, such as the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT),\textsuperscript{33} that rank biomarker-treatment matches into tiers according to strength of evidence, can be used to estimate the clinical value of \(\text{HER2}\) amplification to predict trastuzumab response and guide patient recommendations.\textsuperscript{33–39} Applying ESCAT, evidence from the following sources may be adequate to support off-label trastuzumab: (a) retrospective biomarker analyses of clinical trials originally conducted in an unselected population show the \(\text{HER2}\)-amplified population have better clinical outcomes when trastuzumab is added to chemotherapy for the specific cancer type compared to the \(\text{HER2}\)-nonamplified population, or (b) non-randomized prospective clinical trials show increased tumor shrinkage with the addition of trastuzumab to chemotherapy in the \(\text{HER2}\)-amplified population, but it is not yet known whether this translates to increased survival. Where data are limited to preclinical models or computational (‘in silico’) studies predicting trastuzumab sensitivity, evidence is considered inadequate to recommend off-label trastuzumab as this may not translate to benefit in clinical studies.\textsuperscript{40} Furthermore, relying solely on extrapolated evidence from established indications to infer universal actionability across all cancers is problematic. Actionability may differ between cancers due to differences in intratumoral heterogeneity, tumor microenvironment, and compensatory resistance mechanisms.
may differ across cancers. It is a poor prognostic factor in some cancers, such as breast cancer\textsuperscript{41,42} and USC,\textsuperscript{43} while studies are conflicting in others such as gastric/GE cancer.\textsuperscript{44–46}

Understanding the natural history of the \textit{HER2}-amplified subgroup within a specific cancer type is critical. It offers a default ‘control’ arm to estimate prognosis without trastuzumab when RCTs are not available and trastuzumab benefits are extrapolated from established indications, and for benchmarking clinical outcomes of off-label trastuzumab from single-arm studies. The critical question here is whether the better or worse outcome could be due to trastuzumab or prognosis associated with the \textit{HER2}-amplified cancer type. Alternative sources of natural history data include retrospective biomarker analyses of RCTs, cohort studies, real-world studies, and disease registries. Limitations of these sources include confounding effects from other patient (e.g. age) and tumor (e.g. cancer stage) factors, differences in treatment assessment methods, and supportive treatments. In the absence of randomized comparisons, uncertainty regarding the magnitude of improvement from adding trastuzumab will remain.

\textbf{Signals of trastuzumab activity}

Are there signals of activity for off-label trastuzumab and what is the level of confidence that this will translate to clinically meaningful benefits? Even if scientific rationale exists that \textit{HER2}-amplified cancers are biologically similar across cancer types, evidence of off-label trastuzumab activity on surrogate endpoints in the cancer type of interest increases certainty to support extrapolation. Surrogate endpoints are endpoints used ‘in lieu’ of clinical endpoints because they are more easily measured on a scale to detect differences between treatment groups and/or can be measured earlier, thereby reducing sample size requirements and trial duration. Objective response rate and duration of response are widely used in targeted therapy trials, but these have been shown to correlate poorly with OS in most advanced cancer studies cautioning against overreliance on results based on these endpoints.\textsuperscript{47–49} Surrogate endpoints used for extrapolation should ideally be validated in the cancer type considered for off-label trastuzumab to reliably predict clinical benefit of trastuzumab. As this may not be available, a surrogate validated in the established indication should be used. However, surrogates validated in one cancer may not be a valid surrogate in another and is a limitation of this approach. Thus, uncertainty regarding the validity of the surrogate used for off-label trastuzumab and confidence that results based on these endpoints will translate to clinical benefit will remain.

\textbf{Similarity of safety profile}

Is there evidence to suggest that the safety profile of off-label trastuzumab differs from established indications? It is frequently assumed that the safety profile of off-label trastuzumab is similar to the established indications. However, safety profile can differ across cancers. Trastuzumab used with anthracycline-containing chemotherapy in breast cancer showed greater cardiotoxicity in RCTs than chemotherapy alone (27\% \textit{versus} 8\%), presumably due to additive cardiotoxic effects of anthracyclines.\textsuperscript{6} Although trastuzumab added to anthracycline-free regimens in GE (6\% \textit{versus} 6\%)\textsuperscript{9} and USC trials (3\% \textit{versus} 0\%),\textsuperscript{30} showed no significant increase in cardiac toxicity compared to control therapy. In non-small cell lung cancer, greater cardiac toxicity (6\% \textit{versus} 0\%) was observed when trastuzumab was added to chemotherapy \textit{versus} chemotherapy alone, and it is hypothesized in this cancer, greater smoking history and/or cardiac risk factors may have contributed to this finding.\textsuperscript{40}

The interaction between trastuzumab cardiotoxicity and other cardiac risk factors is likely to be important. Thus, other tumor-specific factors that can impact trastuzumab safety should be considered, such as environmental exposures (e.g. tobacco), organ-specific tumor burden, and residual toxicities from prior therapies. Combining trastuzumab with another cancer therapy adds another layer of complexity and uncertainty for safety.

\textbf{Shared decision-making and informed consent}

How should clinicians engage patients in shared decision making and facilitate informed consent for off-label trastuzumab? ‘Off-label’ therapy commonly refers to a drug used for an indication other than for which it was given market authorization based on judgments of adequate safety and efficacy by a relevant regulatory body.\textsuperscript{51–53} The potential benefits and risks of off-label therapy are always best assessed in clinical trials. Generally, in the clinic, off-label therapy should only be considered when on-label therapies are exhausted, unavailable, or unsuitable for the patient.\textsuperscript{52} Off-label therapy may be justified if
sufficient evidence exists to support a positive benefit-risk assessment. Assuming appropriateness of extrapolation has been assessed and the clinician has judged that sufficient evidence exists to support off-label trastuzumab, the clinician should engage the patient in SDM and facilitate adequate informed consent.

The legal doctrine of informed consent reflects the value placed on a patient’s autonomy and a duty for clinicians to make ‘disclosures which a reasonable medical practitioner would make under the same or similar circumstances’ and what reasonable people would want to know about the prescribed treatment.\(^{54-57}\) SDM refers to the presentation of this information by the clinician as options or choices for the patient and aims to arrive at a mutually acceptable decision based on shared knowledge and the patient’s values and preferences.\(^{56,58,59}\)

SDM and informed consent are particularly important for off-label treatment outside of a clinical trial because there are fewer safeguards and greater medical uncertainty. Potential uncertainties for off-label trastuzumab have been outlined under each extrapolation component.

Financial implications and out-of-pocket costs may be a barrier for access to off-label trastuzumab and should be discussed upfront.\(^{52,60}\) The cost of off-label targeted therapies in general is very expensive (on average $120,000/year in the United States),\(^{61}\) although loss of patent and use of generics can offset some of these costs.\(^{53}\) Financial implications extend beyond the immediate out-of-pocket drug costs and include cost of tumor molecular profiling, supportive medications, toxicity management, costs to payers, such as insurers and/or hospitals who may bear a proportion of the costs, and eventually to taxpayers.\(^{56,60}\) Costs can also have ethical implications and exacerbate access inequities to targeted therapies.\(^{62}\) A more global approach involving health policymakers, payers, clinical trialists, practicing oncologists, and patients will be required to address the issue of cost for off-label therapy. Our framework will serve to provide the impetus for such discussions.

Clinicians should disclose that trastuzumab is being recommended off-label, discuss the rationale for off-label use, areas of uncertainty, and financial implications alongside existing evidence for any alternative therapies. This discussion and ultimate decision should be documented in a written informed consent.\(^{52}\)

**Conclusion**

We have presented a systematic approach for appraising evidence to extrapolate trastuzumab benefits from established indications to off-label use. Criteria for extrapolation, potential reasons and an approach for judging uncertainty, and discussion points to facilitate SDM and informed consent are outlined. HER2-amplified cancers were chosen to illustrate framework application, as much work has been done to understand diagnostic tests, prognosis, and biomarker actionability across diverse cancers. This work is a practical approach for clinicians to guide discussions with multidisciplinary teams and potentially apply them in routine practice. It is potentially generalizable to other biomarker-targeted therapy matches and should be considered by MTBs who make off-label recommendations.

**Declarations**

**Ethics approval and consent to participate**

Ethics approval and informed consent was not required for this study as it did not involve human or animal participants. All data used in our study were obtained from publicly available published studies.

**Consent for publication**

Not applicable.

**Author contribution(s)**

**Doah Cho:** Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Writing – original draft; Writing – review & editing.

**Sarah J. Lord:** Conceptualization; Investigation; Methodology; Supervision; Writing – review & editing.

**John Simes:** Conceptualization; Funding acquisition; Supervision; Writing – review & editing.

**Wendy Cooper:** Conceptualization; Methodology; Supervision; Writing – review & editing.

**Michael Friedlander:** Conceptualization; Writing – review & editing.

**Susie Bae:** Conceptualization; Writing – review & editing.
Chee Khoon Lee: Conceptualization; Investigation; Methodology; Supervision; Writing – review & editing.

Acknowledgements
Not applicable.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the NHMRC Postgraduate Research Scholarship (Medical – Dental) (SC0798) and Postgraduate Research Supplementary Scholarship in Oncology.

Competing Interests
All authors declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 2 years; no other relationships or activities that could appear to have influenced the submitted work. Doah Cho declares support for attending scientific meetings (Novartis). Sarah Lord declares no conflict of interests. John Simes declares research grants to the University of Sydney (Bayer, Roche, BMS, AstraZeneca, Abbvie, MSD, and Pfizer). Wendy Copper declares unpaid consulting or advisory role (Amgen and Bayer). Michael Friedlander declares research grants to institution (AstraZeneca, Novartis, and Beigene), consulting or advisory role (AstraZeneca, GSK, MSD, Lilly, Takeda, Novartis, AGITG independent data monitoring committee, and Steering Committee Member for VELIA trial), honoraria (AstraZeneca, GSK, and ACT Genomics), support for attending scientific meetings and/or travel (AstraZeneca). Susie Bae declares no conflict of interests. Chee Lee declares honoraria (AstraZeneca, Pfizer, Amgen, Takeda, Yuhan, Boehringer Ingelheim, Roche, and MSD Oncology), consulting or advisory role (Novartis, Boehringer Ingelheim, Takeda, AstraZeneca, Yuhan, and Amgen), and research funding (AstraZeneca, Roche, and Merck KGaA).

Availability of data and material
Not applicable.

ORCID iDs
Doah Cho https://orcid.org/0000-0002-8045-0751
Sarah J. Lord https://orcid.org/0000-0003-2763-5949

References
1. Hoefflin R, Lazarou A, Hess ME, et al. Transitioning the molecular tumor board from proof of concept to clinical routine: a German single-center analysis. Cancers 2021; 13: 1151.
2. Luchini C, Lawlor RT, Milella M, et al. Molecular tumor boards in clinical practice. Trends Cancer 2020; 6: 738–744.
3. Rolfo C, Manca P, Salgado R, et al. Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer. ESMO Open 2018; 3: e000398.
4. Harari D and Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000; 19: 6102–6114.
5. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007; 26: 6469–6487.
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–792.
7. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273–1283.
8. Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372: 724–734.
9. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England) 2010; 376: 687–697.
10. Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin–paclitaxel compared with carboplatin–paclitaxel–trastuzumab in advanced (stage III–IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res 2020; 26: 3928–3935.
11. Dumbrava EEI, Balaji K, Raghav K, et al. Targeting ERBB2 (HER2) amplification identified by next-generation sequencing in patients with advanced or metastatic solid tumors beyond conventional indications. JCO Precis Oncol 2019; 3: 1–12.
12. Guyatt GH, Sackett DL and Cook DJ. Users’ guides to the medical literature. II. How to use an
article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. *JAMA* 1994; 271: 59–63.

13. Jaeschke R, Guyatt GH and Sackett DL. Users’ guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. *JAMA* 1994; 271: 703–707.

14. Piggott T, Baldeh T, Dietl B, et al. Standardized wording to improve efficiency and clarity of GRADE ETD frameworks in health guidelines. *J Clin Epidemiol* 2022; 146: 106–122.

15. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. *J Clin Oncol* 2018; 36: 2105–2122.

16. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. *Histopathology* 2008; 52: 797–805.

17. Ross DS, Zehir A, Cheng DT, et al. Next-generation assessment of human epidermal growth factor receptor 2 (ERBB2) amplification status: clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay. *J Mol Diagn* 2017; 19: 244–254.

18. Seol H, Lee HJ, Choi Y, et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. *Modern Pathology* 2012; 25: 938–948.

19. Yang J, Luo H, Li Y, et al. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. *Cell Biochem Biophys* 2012; 62: 221–228.

20. Robinson CL, Harrison BT, Ligon AH, et al. Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays. *Mod Pathol* 2021; 34: 603–612.

21. Cenaj O, Ligon AH, Hornick JL, et al. Detection of ERBB2 amplification by next-generation sequencing predicts HER2 expression in colorectal carcinoma. *Am J Clin Pathol* 2019; 152: 97–108.

22. Nakamura K, Aimono E, Oba J, et al. Estimating copy number using next-generation sequencing to determine ERBB2 amplification status. *Med Oncol* 2021; 38: 36.

23. Connell CM and Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. *ESMO Open* 2017; 2: e000279.

24. Subramanian J, Katta A, Masood A, et al. Emergence of ERBB2 mutation as a biomarker and an actionable target in solid cancers. *Oncologist* 2019; 24: e1303–e1314.

25. Yi Z, Rong G, Guan Y, et al. Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer. *NPJ Breast Cancer* 2020; 6: 59.

26. Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. *Cancer Discov* 2013; 3: 224–237.

27. Mazieres J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. *J Clin Oncol* 2013; 31: 1997–2003.

28. Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. *Clin Cancer Res* 2012; 18: 4910–4918.

29. Ou S-HI, Schrock AB, Bocharov EV, et al. HER2 transmembrane domain (TMD) mutations (V659/G660) that stabilize homo- and heterodimerization are rare oncogenic drivers in lung adenocarcinoma that respond to afatinib. *J Thorac Oncol* 2017; 12: 446–457.

30. Cocco E, Lopez S, Santin AD, et al. Prevalence and role of HER2 mutations in cancer. *Pharmacol Ther* 2019; 199: 188–196.

31. Tsurutani J, Iwata H, Krop I, et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors. *Cancer Discov* 2020; 10: 688–701.

32. Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer. *N Engl J Med* 2022; 386: 241–251.

33. Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). *Ann Oncol* 2018; 29: 1895–1902.

34. Andre F, Mardis E, Salm M, et al. Prioritizing targets for precision cancer medicine. *Ann Oncol* 2014; 25: 2295–2303.

35. Van Allen EM, Wagle N, Stojanov P, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. *Nature Med* 2014; 20: 682–688.
36. Vidwans SJ, Turski ML, Janku F, et al. A framework for genomic biomarker actionability and its use in clinical decision making. *Oncoscience* 2014; 1: 614–623.

37. Meric-Bernstam F, Johnson A, Holla V, et al. A decision support framework for genomically informed investigational cancer therapy. *J Natl Cancer Inst* 2015; 10: djv098.

38. Chakravarty D, Gao J, Phillips SM, et al. OncoKB: a precision oncology knowledge base. *JCO Precis Oncol* 2017; 2017: PO.17.0011.

39. Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. *J Mol Diagn* 2017; 19: 4–23.

40. Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemicitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. *Ann Oncol* 2004; 15: 19–27.

41. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987; 235: 177–182.

42. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science* 1989; 244: 707–712.

43. Morrison C, Zanagno V, Ramirez N, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. *J Clin Oncol* 2006; 24: 2376–2385.

44. Jorgensen JT and Horsm M. HER2 as a prognostic marker in gastric cancer: a systematic analysis of data from the literature. *J Cancer* 2012; 3: 137–144.

45. Shitara K, Yatabe Y, Matsuo K, et al. Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. *Gastric Cancer* 2013; 16: 261–267.

46. Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. *Ann Oncol* 2012; 23: 2656–2662.

47. Haslam A, Hey SP, Gill J, et al. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. *Eur J Cancer* 2019; 106: 196–211.

48. Gyawali B, Hey SP and Kesselheim AS. Evaluating the evidence behind the surrogate measures included in the FDA’s table of surrogate endpoints as supporting approval of cancer drugs. *EClinicalMedicine* 2020; 21: 100332.

49. Kim C and Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. *JAMA Intern Med* 2015; 175: 1992–1994.

50. Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. *J Clin Oncol* 2018; 36: 2044–2051.

51. Casali PG. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). *Ann Oncol* 2007; 18: 1923–1925.

52. Council of Australian Therapeutic Advisory Groups. Rethinking medicines decision-making in Australian Hospitals: Guiding Principles for the quality use of off-label medicines. Council of Australian Therapeutic Advisory Groups; 2013. Darlinghurst, New South Wales, 2010.

53. Levêque D. Off-label use of targeted therapies in oncology. *World J Clin Oncol* 2016; 7: 253.

54. Natanson v. Kline, Supreme Court of Kansas. p. P.2d 1093 (1960).

55. Canterbury v. Spence, D.C. Circuit (1972).

56. Wilkes M and Johns M. Informed consent and shared decision making: a model for clinical practice. *J Gen Intern Med* 2012; 27: 1361–1367.

57. Furey K and Wilkins K. Prescribing “off-label” prescriptions. *PLoS Med* 2008; 5: e223.

58. Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. *J Gen Intern Med* 2012; 27: 1361–1367.

59. Micale F. Prescribing “off-label”: what should a physician disclose? *AMA J Ethics* 2016; 18: 587–593.

60. de Souza JA. Advances in drug development: off-label drug utilization in oncology. *Clin Adv Hematol Oncol* 2011; 9: 473–475.

61. Mailankodi S and Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. *JAMA Oncol* 2015; 1: 539–540.

62. Madhusoodanan J. Health-care inequality could deepen with precision oncology. *Nature* 2020; 585: S13–S15.